用于治疗发炎性肠道疾病的蛋白质水解物市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

2024 年全球用于治疗发炎性肠道疾病的蛋白质水解物市场价值为 9.956 亿美元，预计到 2034 年将以 5.5% 的复合年增长率增长至 17 亿美元。

产业扩张持续受益于强有力的科学支持，近期临床研究结果进一步证实了其治疗价值。这些产品在拥有完善诊断体系和先进医疗能力的地区，尤其是在发炎性肠道疾病（IBD）检出率较高的市场，正获得广泛认可。亚太等快速成长地区，由于人们对IBD的认知度不断提高以及发病率呈上升趋势（尤其是在东亚地区），市场成长速度正在加快。重塑市场格局的另一个动力是全球对植物性营养的日益增长的需求。随着纯素食和素食生活方式的普及，对植物蛋白水解物的需求急剧上升，相关研究也证实了其在控制发炎和促进肠道健康方面的潜力。此外，专业医疗营养的普及也推动了市场需求，蛋白水解物正成为慢性消化系统疾病患者治疗性饮食策略的重要组成部分。

2024年，深度水解蛋白製剂市占率达到38%，这主要得益于其适用于重度发炎性肠道疾病以及市场对高消化率、低抗原解决方案的需求。这些产品被加工成更小的营养成分，有助于减少免疫触发因素，同时仍能提供维持肠道功能和促进康復所需的关键营养素。由于在支持需要精准营养介入的患者方面卓有成效，临床接受度持续上升。

2024年，肠内营养市占率达42%。此类别广泛应用于需要透过餵食系统或流质饮食管理获得营养支持的发炎性肠道疾病患者。临床证据不断强调肠内营养的益处，尤其是在常规疗法效果不佳的情况下。其强劲的市场表现也反映出人们对特殊营养方案在疾病急性发作控制方面的持续依赖。

2024年，美国用于治疗发炎性肠道疾病（IBD）的蛋白质水解物市场规模预计将达到3.304亿美元，主要得益于庞大的IBD患者族群（约占总人口的0.72%）。该地区完善的医疗保健体系、活跃的临床研究环境、支持性的医疗营养法规以及保险覆盖范围，都促进了该产品的快速普及。主要研究机构正在进行的研究也凸显了该地区致力于改善治疗性营养并保持其领先地位的决心。

参与发炎性肠道疾病蛋白水解物市场的主要公司包括Kerry Group plc、Arla Foods Ingredients、Abbott Nutrition、Nestle Health Science、Fresenius Kabi、Nutricia、Reckitt、Ajinomoto和DSM Nutritional Products。这些公司正透过大力投资临床研究来扩大市场份额，以验证治疗优势并获得更广泛的医学认可。许多製造商正在改进生产技术，以提高蛋白质消化率并降低抗原性，从而满足患有严重胃肠道疾病患者的需求。此外，为了迎合消费者对纯素食和素食医疗营养品日益增长的需求，各公司也正在拓展植物性水解物产品组合。与医疗机构进行策略合作、致力于研发先进的肠内营养製剂以及拓展高成长地区是其竞争策略的核心。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 利润率
  • 每个阶段的价值增加
  • 影响价值链的因素
  • 中断
• 产业影响因素
  • 成长驱动因素
  • 产业陷阱与挑战
  • 市场机会
• 成长潜力分析
• 监管环境
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 波特的分析
• PESTEL 分析
• 价格趋势
  • 按地区
• 未来市场趋势
• 技术与创新格局
  • 当前技术趋势
  • 新兴技术
• 专利格局
• 贸易统计（HS编码）（註：仅提供重点国家的贸易统计资料）
  • 主要进口国
  • 主要出口国
• 永续性和环境方面
  • 永续实践
  • 减少废弃物策略
  • 生产中的能源效率
  • 环保倡议
• 碳足迹考量

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 合作伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场规模及预测：依产品类型划分，2021-2034年

• 主要趋势
• 深度水解蛋白质产品
• 部分水解蛋白产品
• 胺基酸配方
• 其他的

第六章：市场规模及预测：依原料划分，2021-2034年

• 主要趋势
• 乳製品水解物
  • 乳清蛋白水解物
  • 酪蛋白水解物
  • α-乳清蛋白浓缩物
  • 其他的
• 植物水解物
  • 米蛋白水解物
  • 豌豆蛋白水解物
  • 大豆蛋白水解物
  • 其他的
• 海洋来源水解物
• 其他的

第七章：市场规模及预测：依应用领域划分，2021-2034年

• 主要趋势
• 肠内营养
• 口服营养补充品
• 医用食品
• 其他的

第八章：市场规模及预测：依最终用途划分，2021-2034年

• 主要趋势
• 医院和临床机构
• 家庭医疗保健
• 专业营养中心
• 其他的

第九章：市场规模及预测：依地区划分，2021-2034年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第十章：公司简介

• Kerry Group
• Arla Foods Ingredients
• Abbott Nutrition
• Nestle Health Science
• Fresenius Kabi
• Nutricia
• Reckitt
• Ajinomoto
• DSM Nutritional Products

The Global Protein Hydrolysates for Inflammatory Bowel Disease Market was valued at USD 995.6 million in 2024 and is estimated to grow at a CAGR of 5.5% to reach USD 1.7 billion by 2034.

Industry expansion continues to benefit from strong scientific support, as recent clinical findings reinforce their therapeutic value. These products are gaining traction across regions with established diagnostic systems and advanced healthcare capabilities, particularly in markets where IBD detection rates are high. Areas experiencing rapid growth, such as Asia Pacific, are accelerating due to rising awareness and increasing incidence trends, especially in East Asia. Another major force reshaping the market is the growing global shift toward plant-based nutrition. As vegan and vegetarian lifestyles expand, demand for plant-derived protein hydrolysates is rising sharply, supported by research that highlights their potential in managing inflammation and supporting gut health. Market interest is also driven by the broader trend toward specialized medical nutrition, where protein hydrolysates are becoming an important part of therapeutic dietary strategies for individuals managing chronic digestive conditions.

The extensively hydrolyzed protein formulations segment held a 38% share in 2024, driven by their suitability for severe inflammatory bowel disease and the need for highly digestible, low-antigen solutions. These products are processed into smaller nutritional components, helping reduce immune triggers while still supplying key nutrients essential for maintaining intestinal function and promoting recovery. Their clinical acceptance continues to rise due to their effectiveness in supporting patients requiring precise nutritional interventions.

The enteral nutrition segment held a 42% share in 2024. This category is widely used for individuals with inflammatory bowel disease who require nutritional support through feeding systems or liquid-based dietary management. Clinical evidence consistently highlights the benefits of enteral nutrition, particularly in cases where conventional therapies are insufficient, and its strong performance reflects continued reliance on specialized nutritional regimens for managing disease flares.

U.S. Protein Hydrolysates for Inflammatory Bowel Disease Market generated USD 330.4 million in 2024, supported by a significant IBD patient pool, with about 0.72% of the population affected. The region's robust healthcare systems, active clinical research landscape, supportive regulations for medical nutrition, and insurance coverage contribute to strong adoption. Ongoing studies led by major research institutions underscore the region's commitment to improving therapeutic nutrition and maintaining its leadership position.

Key companies participating in the Protein Hydrolysates for Inflammatory Bowel Disease Market industry include Kerry Group plc, Arla Foods Ingredients, Abbott Nutrition, Nestle Health Science, Fresenius Kabi, Nutricia, Reckitt, Ajinomoto, and DSM Nutritional Products. Companies in the Protein Hydrolysates for Inflammatory Bowel Disease Market are widening their market footprint by investing heavily in clinical research to validate therapeutic advantages and secure stronger medical acceptance. Many manufacturers are refining production technologies to enhance protein digestibility and reduce antigenicity, helping them meet the needs of patients with severe gastrointestinal challenges. Firms are also diversifying their portfolios with plant-based hydrolysates to align with rising consumer preference for vegan and vegetarian medical nutrition. Strategic collaborations with healthcare institutions, product innovation geared toward advanced enteral formulations, and expansion into high-growth regions are central to their competitive approach.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Product type
  • 2.2.2 Source material
  • 2.2.3 Application
  • 2.2.4 End Use
• 2.3 TAM analysis, 2025-2034
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Industry pitfalls and challenges
  • 3.2.3 Market opportunities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
  • 3.7.1 By region
• 3.8 Future market trends
• 3.9 Technology and innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent landscape
• 3.11 Trade statistics (HS code) (Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries
• 3.12 Sustainability and environmental aspects
  • 3.12.1 Sustainable practices
  • 3.12.2 Waste reduction strategies
  • 3.12.3 Energy efficiency in production
  • 3.12.4 Eco-friendly initiatives
• 3.13 Carbon footprint considerations

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 Latin America
    • 4.2.1.5 Middle East & Africa
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Size and Forecast, By Product Type, 2021-2034 (USD Billion, Kilo Tons)

• 5.1 Key trends
• 5.2 Extensively hydrolyzed protein products
• 5.3 Partially hydrolyzed protein products
• 5.4 Amino acid-based formulations
• 5.5 Others

Chapter 6 Market Size and Forecast, By Source Material, 2021-2034 (USD Billion, Kilo Tons)

• 6.1 Key trends
• 6.2 Dairy-derived hydrolysates
  • 6.2.1 Whey protein hydrolysates
  • 6.2.2 Casein hydrolysates
  • 6.2.3 Alpha-lactalbumin concentrates
  • 6.2.4 Others
• 6.3 Plant-based hydrolysates
  • 6.3.1 Rice protein hydrolysates
  • 6.3.2 Pea protein hydrolysates
  • 6.3.3 Soy protein hydrolysates
  • 6.3.4 Others
• 6.4 Marine-derived hydrolysates
• 6.5 Others

Chapter 7 Market Size and Forecast, By Application, 2021-2034 (USD Billion, Kilo Tons)

• 7.1 Key trends
• 7.2 Enteral nutrition
• 7.3 Oral nutritional supplements
• 7.4 Medical foods
• 7.5 Others

Chapter 8 Market Size and Forecast, By End Use, 2021-2034 (USD Billion, Kilo Tons)

• 8.1 Key trends
• 8.2 Hospitals & clinical settings
• 8.3 Home healthcare
• 8.4 Specialized nutrition centers
• 8.5 Others

Chapter 9 Market Size and Forecast, By Region, 2021-2034 (USD Billion, Kilo Tons)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 UK
  • 9.3.2 Germany
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 South Korea
  • 9.4.5 Australia
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Kerry Group
• 10.2 Arla Foods Ingredients
• 10.3 Abbott Nutrition
• 10.4 Nestle Health Science
• 10.5 Fresenius Kabi
• 10.6 Nutricia
• 10.7 Reckitt
• 10.8 Ajinomoto
• 10.9 DSM Nutritional Products